Bioverativ (BIVV) Earning Somewhat Positive News Coverage, Study Finds
Headlines about Bioverativ (NASDAQ:BIVV) have been trending somewhat positive on Friday, Accern Sentiment reports. Accern identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Bioverativ earned a coverage optimism score of 0.17 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 45.5826753876032 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the media stories that may have effected Accern’s rankings:
- Bioverativ Inc. (NASDAQ:BIVV) – What’s Better? – Buy or Sell – Nasdaq Journal (press release) (nasdaqjournal.com)
- Hot Stock under Review – Bioverativ Inc. (NASDAQ: BIVV) – Alpha Beta Stock (alphabetastock.com)
- William Blair Weighs in on Bioverativ Inc’s FY2017 Earnings (BIVV) (americanbankingnews.com)
- Investors may need a consensus Analysts Rating: Bioverativ Inc. (BIVV) – Wall Street Morning (wallstreetmorning.com)
- Analysts’ Recommendation in Spotlight: Bioverativ Inc (NASDAQ: BIVV) – Alpha Beta Stock (alphabetastock.com)
Bioverativ (NASDAQ:BIVV) traded up $1.04 during trading hours on Friday, hitting $63.75. 1,557,600 shares of the stock were exchanged, compared to its average volume of 1,110,000. The firm has a market capitalization of $6,900.00 and a price-to-earnings ratio of 15.59. Bioverativ has a twelve month low of $40.00 and a twelve month high of $64.68.
BIVV has been the subject of a number of research reports. Zacks Investment Research upgraded shares of Bioverativ from a “hold” rating to a “buy” rating and set a $60.00 target price for the company in a research report on Monday, January 1st. Argus upgraded shares of Bioverativ from a “hold” rating to a “buy” rating and set a $64.00 target price for the company in a research report on Wednesday, September 20th. Deutsche Bank set a $53.00 target price on shares of Bioverativ and gave the stock a “hold” rating in a research report on Monday, November 20th. Piper Jaffray Companies reissued an “overweight” rating and issued a $71.00 price objective on shares of Bioverativ in a research report on Monday, October 23rd. Finally, Royal Bank of Canada began coverage on shares of Bioverativ in a research report on Thursday, September 14th. They issued a “sector perform” rating and a $59.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. Bioverativ presently has a consensus rating of “Hold” and an average target price of $60.47.
Bioverativ Company Profile
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Receive News & Ratings for Bioverativ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ and related companies with MarketBeat.com's FREE daily email newsletter.